At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Ifosfamide +2 moredrug
Likely dose
Ifosfamide 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis
In Brief
A Phase 2 clinical trial evaluating Ifosfamide, Paclitaxel (Taxol), and 1 other intervention for Penile Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPenile Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 1999
First PostedAug 2007
Primary CompletionAug 2010
TodayJul 2026
First PostedAug 7, 2007
Enrollment StartAug 1, 1999
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 18.9 years ago
Interventions
Ifosfamidedrug
1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
Paclitaxel (Taxol)drug
175 mg/m\^2 By Vein Over 3 Hours on Day 1
Cisplatindrug
25 mg/m\^2 By Vein Over 2 Hours on Days 1-3